Anúncio
Anúncio
PRLD
Prelude Therapeutics Incorporated
2.65
USDPatrocinado
-0.11
-3.99%
09 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
2.63
-0.02
-0.57%
Relatórios de Lucros PRLD
Rácio de surpresa positiva
PRLD separação 15 de 21 últimas estimativas.
71%
Próximo Relatório
Data do Próximo Relatório
09 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$35.70M
/-$0.02
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+449.23%
/-92.31%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+792.50%
/-94.74%
Prelude Therapeutics Incorporated earnings per share and revenue
On 12 de nov. de 2025, PRLD reported earnings of -0.26 USD per share (EPS) for Q3 25, beating the estimate of -0.37 USD, resulting in a 30.22% surprise. Revenue reached 6.50 milhão, compared to an expected --, with a 0.00% difference. The market reacted with a +8.89% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analistas forecast an EPS of -0.02 USD, with revenue projected to reach 35.70 milhão USD, implying an diminuir of -92.31% EPS, and aumentar of 449.23% in Revenue from the last quarter.
FAQ
What were Prelude Therapeutics Incorporated's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Prelude Therapeutics Incorporated reported EPS of -$0.26, beating estimates by 30.22%, and revenue of $6.50M, 0% as expectations.
How did the market react to Prelude Therapeutics Incorporated's Q3 2025 earnings?
The stock price moved up 8.89%, changed from $1.35 before the earnings release to $1.47 the day after.
When is Prelude Therapeutics Incorporated expected to report next?
The next earning report is scheduled for 09 de mar. de 2026.
What are the forecasts for Prelude Therapeutics Incorporated's next earnings report?
Based on 5
analistas, Prelude Therapeutics Incorporated is expected to report EPS of -$0.02 and revenue of $35.70M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio